For instance, a recent study found that a deviating concentration of the isoenzyme CA-IX may provide a future target in terms of a biomarker to identify severe OSA or patients particularly suitable for a drug with CA inhibitory properties [27]. The gene discussed is CA9; the disease is obstructive sleep apnea syndrome.